|
1
|
Mario S: Long-term survival outcomes with
new treatments for advanced melanoma: Questions still in need of
answers (ASCO post) Available from: https://ascopost.com/issues/october-25-2019/long-term-survival-outcomes-with-new-treatments-for-advanced-melanoma/.
Accessed June 30, 2020.
|
|
2
|
Chapman PB, Einhorn LH, Meyers ML, Saxman
S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM,
Ernstoff MS, et al: Phase III multicenter randomized trial of the
Dartmouth regimen versus dacarbazine in patients with metastatic
melanoma. J Clin Oncol. 17:2745–2751. 1999.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Middleton MR, Grob JJ, Aaronson N,
Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates
A, et al: Randomized phase III study of temozolomide versus
dacarbazine in the treatment of patients with advanced metastatic
malignant melanoma. J Clin Oncol. 18:158–166. 2000.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lorigan P, Marples M, Harries M, Wagstaff
J, Dalgleish AG, Osborne R, Maraveyas A, Nicholson S, Davidson N,
Wang Q, et al: Treatment patterns, outcomes, and resource
utilization of patients with metastatic melanoma in the U.K: The
MELODY study. Br J Dermatol. 170:87–95. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D,
Ferrucci PF, et al: Overall survival with combined nivolumab and
ipilimumab in advanced melanoma. N Engl J Med. 377:1345–1356.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and
placebo for Val600 BRAF-mutant melanoma: A multicentre,
double-blind, phase 3 randomised controlled trial. Lancet.
386:444–451. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kong BY, Carlino MS and Menzies AM:
Biology and treatment of BRAF mutant metastatic melanoma. Melanoma
Manag. 3:33–45. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Minor DR, Moore D, Kim C, Kashani Sabet M,
Venna SS, Wang W, Boasberg P and O'Day S: Prognostic factors in
metastatic melanoma patients treated with biochemotherapy and
maintenance immunotherapy. Oncologist. 14:995–1002. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hauschild A, Larkin J, Ribas A, Dréno B,
Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y and
McArthur GA: Modelled prognostic subgroups for survival and
treatment outcomes in BRAF V600-Mutated metastatic melanoma: Pooled
analysis of 4 randomized clinical trials. JAMA Oncol. 4:1382–1388.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jungnelius U, Ringborg U, Aamdal S,
Mattsson J, Stierner U, Ingvar C, Malmström P, Andersson R,
Karlsson M, Willman K, et al: Dacarbazine-vindesine versus
dacarbazine-vindesine-cisplatin in disseminated malignant melanoma.
A randomised phase III trial. Eur J Cancer. 34:1368–1374.
1998.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Legha SS, Ring S, Bedikian A, Plager C,
Eton O, Buzaid AC and Papadopulos N: Treatment of metastatic
melanoma with combined chemotherapy containing cisplatin,
vinblastine and dacarbazine (CVD) and biotherapy using
interleukin-2 and interferon-alpha. Ann Oncol. 7:827–835.
1996.PubMed/NCBI View Article : Google Scholar
|
